Elutia, Inc. is a clinical‐stage biotechnology company focused on the discovery and development of next‐generation immuno‐oncology therapies. The company’s core mission is to deliver novel biologic and small‐molecule candidates designed to modulate the tumor microenvironment and enhance anti‐tumor immune responses. Through its proprietary RASSO platform, Elutia integrates high‐throughput screening, structure‐guided design, and advanced immunoassays to identify lead compounds with the potential to address solid and hematologic malignancies with unmet medical need.
Elutia’s pipeline features multiple preclinical and early‐stage clinical programs. Its lead candidate, ELU‐101, is a bispecific antibody engineered to engage both T cells and tumor antigens, aiming to improve selectivity and reduce off‐target effects. In parallel, the company is advancing ELU‐201, a small‐molecule checkpoint modulator designed to restore immune surveillance in resistant tumors. Both programs leverage Elutia’s deep expertise in antibody engineering, cellular immunology, and translational pharmacology to accelerate development timelines and optimize patient outcomes.
Since its founding in 2015, Elutia has established research operations in Cambridge, Massachusetts, and maintains strategic collaborations with leading academic institutions and contract research organizations across North America and Europe. These partnerships support rigorous preclinical validation and enable streamlined progression into clinical trials. In addition, Elutia has secured manufacturing alliances to ensure scalable production of both biologics and small‐molecule assets, positioning the company to meet anticipated demand should its candidates advance successfully through regulatory review.
Elutia is led by a management team with extensive experience in biopharmaceutical development, regulatory affairs, and commercial strategy. Chief Executive Officer Dr. Jane Meadows previously held leadership roles at several biotechnology firms where she oversaw late‐stage oncology programs and successful product launches. The company’s board and scientific advisory panel include experts in immunology, structural biology, and clinical oncology, providing strategic guidance as Elutia works toward delivering innovative cancer therapies to patients worldwide.
AI Generated. May Contain Errors.
